ATP7bIL24f
ICGi020-B
General
Cell Line |
|
hPSCreg name | ICGi020-B |
Cite as: | ICGi020-B (RRID:CVCL_ZE01) |
Alternative name(s) |
ATP7bIL24f
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
AHQUi001-A (IPS35-2) Donor's gene variants: LPL Donor diseases: NON RARE IN EUROPE: Hyperlipoproteinemia type 4 |
Last update | 14th April 2022 |
User feedback | |
Provider |
|
Generator | Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG) |
Owner | Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG) |
Distributors | |
Derivation country | Russia |
External Databases |
|
BioSamples | SAMEA6983567 |
Cellosaurus | CVCL_ZE01 |
Wikidata | Q98126762 |
General Information |
|
Publications | |
* Is the cell line readily obtainable for third parties? |
Yes Cell line can only be used in: Personalized genomic profiling in human orphan diseases
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Additional restrictions:
N/A |
Donor Information
General Donor Information |
|
Sex | male |
Age of donor (at collection) | 15-19 |
Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
Yes
46, XY
Karyotyping method:
G-Banding
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
Yes
|
Donor Relations |
|
Other cell lines of this donor | |
External Databases (Donor) |
|
BioSamples | SAMEA6938908 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Alternatives to consent are available? | No |
Is there other documentation provided to the donor for consenting purposes? | No |
Confirm that consent was obtained by a qualified professional | Yes |
Has the donor agreed to be re-contacted? | Yes |
Has the donor been informed about how her/his data will be protected? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent pertain to a specific research project? | Yes |
Details on restriction to research project | Personalized genomic profiling in human orphan diseases |
Does consent permit unforeseen future research, without further consent? | Yes |
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
Does consent expressly prevent development of commercial products? | Yes |
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
an academic institution? | Yes |
a public organisation? | No |
a non-profit company? | Yes |
a for-profit corporation? | No |
Does consent expressly permit collection of genetic information? | Yes |
Does consent expressly permit storage of genetic information? | Yes |
Does consent prevent dissemination of genetic information? | No |
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | Yes |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Research Ethics Committee of the Research Institute of Medical Genetics of the Tomsk National Research Medical Center (Tomsk, Russia) |
Approval number | Protocol number 125/1 (22.10.2018) |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | Research Ethics Committee of the Research Institute of Medical Genetics of the Tomsk National Research Medical Center (Tomsk, Russia) |
Approval number | Protocol number 125/1 (22.10.2018) |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
Source cell origin |
A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.
Synonyms
|
Age of donor (at collection) | 15-19 |
Collected in | 2019 |
Passage number reprogrammed | 1 |
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Episomal |
Genes | |
Is reprogramming vector detectable? |
No |
Methods used |
PCR
|
Files and images showing reprogramming vector expressed or silenced | |
Vector map | |
Vector free reprogramming |
|
Type of used vector free reprogramming factor(s) |
None
|
Other |
|
Selection criteria for clones | ESC-like morphology |
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Gelatin | ||||||||||||||||||
Feeder cells |
Mouse embryonic fibroblasts |
||||||||||||||||||
Passage method |
Enzymatically
TrypLE
|
||||||||||||||||||
O2 Concentration | 20 % | ||||||||||||||||||
CO2 Concentration | 5 % | ||||||||||||||||||
Medium |
Other medium:
Base medium: Knock-out DMEM
Main protein source: Knock-out serum replacement Serum concentration: 15 % Supplements
|
||||||||||||||||||
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
||||||||||||||||||
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
||||||||||||||||||
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
Alkaline Phosphatase |
Yes |
|||||
NANOG |
Yes |
|||||
SSEA-4 |
Yes |
|||||
POU5F1 (OCT-4) |
Yes |
|||||
TRA 1-60 |
Yes |
Morphology pictures
Differentiation Potency
In vitro spontaneous differentiation
Marker | Expressed |
Hepatocyte nuclear factor 3-beta |
Yes |
CK-18 |
Yes |
Microbiology / Virus Screening |
|
Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.